HTA Council Recommendation (as of 16 June 2021) As final recommendation, the HTA Council does not recommend the inclusion of lapatinib [250 mg tablet] for the treatment of HER2-positive breast cancer in the Philippine National Formulary (PNF). Relevant Information Evidence and Relevant Documents Assessment History Back to Assessments Page
Insulin glargine [100 U/mL solution for injection] for the treatment of Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM)
HTA Council Recommendation (as of 03 October 2022) As final recommendation, the HTA Council recommends the government financing and inclusion of insulin glargine [100 U/mL solution for injection] for the treatment of Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM) in the Philippine National Formulary (PNF). Relevant Information Evidence and Relevant Documents continue reading : Insulin glargine [100 U/mL solution for injection] for the treatment of Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM)
Insulin detemir [100 U/mL solution for injection] for the treatment of Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM)
HTA Council Recommendation (as of 03 October 2022) As final recommendation, the HTA Council does not recommend the government financing and inclusion of insulin detemir [100 U/mL solution for injection] for the treatment of Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM) in the Philippine National Formulary (PNF). Relevant Information Evidence and continue reading : Insulin detemir [100 U/mL solution for injection] for the treatment of Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM)
Gadobutrol [Pre-filled syringe 1 mmol/mL (7.5 mL) Vial 1 mmol/mL (7.5 mL)] for diagnostic magnetic resonance imaging (MRI) in adults and children
HTA Council Recommendation (as of 11 June 2026) As a final recommendation, the HTA Council recommends the government financing of the following: for use in diagnostic magnetic resonance imaging (MRI) in adults and children. Relevant Information Evidence and Relevant Documents Assessment History Back to Assessments Page
Lenvatinib [4 mg/10 mg capsule] for the treatment of advanced or unresectable hepatocellular cancer (HCC) among adults
HTA Council Recommendation (as of 19 January 2026) As a final recommendation, the HTA Council recommends the government financing of Lenvatinib [4 mg/10 mg capsule] as first-line treatment for adults diagnosed with advanced or unresectable HCC who are not candidates for immunotherapy and/oranti-VEGF. Relevant Information Evidence and Relevant Documents Assessment History Back to Assessments Page